Mucopolysaccharides (MPS) Screen Qualitative - Urine

Mucopolysaccharides (MPS) Screen Qualitative - Urine is a preliminary biochemical test used to check a urine specimen for an abnormal increase or pattern of mucopolysaccharides, which are now more commonly called glycosaminoglycans or GAGs. The test supports the investigation of mucopolysaccharidoses, a group of uncommon inherited lysosomal storage disorders.

Glycosaminoglycans are long, complex carbohydrate chains found throughout the body. They contribute to the normal structure and function of cartilage, bone, skin, tendons, corneas, blood vessels, heart valves and other connective tissues. The body continuously produces, uses and breaks down these molecules through specialised enzymes located within cellular structures called lysosomes.

In a mucopolysaccharidosis, a specific lysosomal enzyme is absent, reduced or unable to function correctly. Consequently, one or more glycosaminoglycans cannot be broken down normally. Partially degraded material accumulates inside cells and may be excreted in increased quantities through urine. Progressive accumulation can affect several organs and body systems.

This qualitative urine test is generally used as an initial screen. The result may be reported as positive, negative, detected, not detected or as an abnormal mucopolysaccharide pattern. It does not provide the detailed numerical measurement or subtype-specific information available from quantitative GAG analysis using advanced mass spectrometry.

A positive result does not independently diagnose a particular MPS disorder. A negative result also cannot exclude every type, mild form or later presentation of mucopolysaccharidosis. When clinical suspicion remains, doctors may recommend quantitative urine or blood GAG analysis, GAG fractionation, specific lysosomal enzyme assays and molecular genetic testing.

Benefits of MPS Qualitative Urine Screening

The qualitative MPS urine screen provides an accessible preliminary assessment when a mucopolysaccharidosis is suspected. It can indicate whether additional specialised biochemical and genetic investigations are warranted. Early investigation is important because several MPS disorders are progressive, and disease-specific management may be more beneficial when started before irreversible organ damage develops.

• Provides a preliminary screen for abnormal urinary mucopolysaccharides or glycosaminoglycans.
• Supports investigation of patients with features suggestive of a lysosomal storage disorder.
• Uses a non-invasive urine specimen that is usually straightforward to collect.
• May help identify patients who require quantitative GAG analysis.
• Supports decisions regarding specific lysosomal enzyme testing.
• May contribute to the investigation of unexplained skeletal, connective-tissue, neurological or organ abnormalities.
• Can assist paediatricians and metabolic specialists in planning further diagnostic evaluation.
• Complements clinical examination, imaging, cardiac assessment, hearing evaluation and ophthalmological testing.
• May support family counselling when combined with confirmatory biochemical and genetic results.
• Provides a cost-effective initial investigation before advanced subtype-specific testing.

What Are Mucopolysaccharidoses?

Mucopolysaccharidoses are inherited metabolic diseases caused by deficiencies of enzymes required to degrade specific glycosaminoglycans. The major clinical categories include MPS I, MPS II, MPS III, MPS IV, MPS VI, MPS VII and MPS IX, with additional subtypes based on the deficient enzyme and genetic cause.

Different MPS disorders cause different patterns of glycosaminoglycan accumulation. Dermatan sulfate and heparan sulfate may be increased in several disorders, including MPS I and MPS II. Heparan sulfate is particularly relevant to MPS III, while keratan sulfate may be associated with MPS IV. The exact pattern is better assessed using quantitative and fractionation methods than by a basic qualitative screen.

Most MPS disorders follow an autosomal recessive inheritance pattern, meaning an affected individual usually inherits one altered gene copy from each parent. MPS II, also known as Hunter syndrome, is generally inherited in an X-linked pattern and predominantly affects males. A urine screening result cannot determine inheritance or carrier status.

Clinical Indications and Applications

Skeletal and Joint Abnormalities: Doctors may request MPS screening for patients with abnormal bone development, short stature, joint stiffness, joint laxity, spinal curvature, chest-wall abnormalities, hip problems, enlarged skull or a radiological pattern called dysostosis multiplex.

Developmental or Neurological Concerns: Some MPS types can cause developmental delay, loss of previously acquired skills, learning difficulties, behavioural changes, sleep disturbance or progressive neurological impairment. Other forms predominantly affect the skeleton and internal organs while intelligence remains unaffected.

Coarse Facial Features and Connective-Tissue Changes: Progressive facial coarsening, thick hair, enlarged tongue, thickened skin, umbilical or inguinal hernia and limited joint movement may raise clinical suspicion. These signs vary widely and may be subtle during early childhood.

Organ Enlargement: Glycosaminoglycan accumulation may enlarge the liver or spleen. Affected patients may also develop recurrent respiratory infections, obstructive sleep apnoea, airway narrowing or reduced exercise capacity.

Cardiac, Hearing and Vision Findings: MPS disorders may affect heart valves, heart muscle, coronary arteries, hearing and vision. Corneal clouding occurs in some types but may be absent in others. Recurrent ear infections and progressive hearing loss can occur during childhood.

Family History or Abnormal Newborn Screening: Testing may form part of a broader work-up when a relative has an MPS disorder, prenatal risk has been identified or a newborn screening programme reports a concerning result. A basic urine screen is not a substitute for targeted confirmatory testing.

Why Doctors Recommend This Test

MPS disorders can initially resemble more common childhood conditions. Recurrent infections, hernias, joint problems, delayed development or skeletal abnormalities may occur separately before the overall pattern becomes apparent. A urine MPS screen may provide an early biochemical clue that helps direct the patient to specialised testing.

The test is particularly useful as a preliminary investigation because glycosaminoglycan fragments can be excreted in urine when their degradation is impaired. However, urinary excretion varies with age, disease type, disease severity, kidney function, hydration and analytical method. Infants and young children naturally excrete more GAGs than adults, making age-appropriate interpretation essential.

Doctors generally interpret the result together with a detailed history, three-generation family history, physical examination, skeletal imaging, echocardiography, hearing assessment, eye examination and neurological or developmental evaluation. The pattern of clinical findings guides the selection of confirmatory enzyme and genetic tests.

Preparation Before the Test

Fasting is generally not required. The patient should follow their usual diet and maintain normal hydration unless the doctor or laboratory provides different instructions. Excessive water intake shortly before collection should be avoided because it may excessively dilute the urine specimen.

Inform the doctor and laboratory about the patient's age, symptoms, family history, current medicines, previous transfusions and any earlier newborn, enzyme or genetic test results. Age is especially important because normal urinary glycosaminoglycan excretion changes considerably during growth.

Do not discontinue medicines or supplements without medical advice. If the patient has a urinary tract infection, fever, diarrhoea, severe dehydration or another acute illness, ask the referring doctor whether the specimen should be collected immediately or after recovery.

Urine Sample Collection Procedure

A fresh urine specimen is collected in a clean, dry, laboratory-approved container. A random specimen may be acceptable unless the laboratory specifically requests an early-morning or timed sample. The collection centre's instructions always take priority because requirements vary by analytical method.

For a clean-catch specimen, wash and dry the hands before collection. When possible, begin urinating into the toilet, collect the middle portion directly in the container and finish urinating into the toilet. Avoid touching the inside of the container or lid.

For infants and young children, the laboratory may provide a paediatric urine collection bag. The bag should be checked frequently and removed promptly after urination. Urine squeezed from a diaper is unsuitable because absorbent material can contaminate the specimen and alter its composition.

Prevent contamination with stool, tissue paper, soap, disinfectant, powder or toilet water. Close the container securely, label it correctly and return it promptly. The laboratory may require refrigeration or freezing for transport. An insufficient, leaking, contaminated or incorrectly stored specimen may need to be recollected.

Laboratory Screening Method

Traditional qualitative MPS screening methods use chemical reactions or electrophoretic techniques to detect increased urinary glycosaminoglycans or an abnormal migration pattern. The precise method and reporting criteria depend on the performing laboratory. The report may state that the screen is positive, negative, normal or abnormal.

Modern quantitative methods can measure specific GAG-derived markers such as dermatan sulfate, heparan sulfate, keratan sulfate and chondroitin sulfate using liquid chromatography-tandem mass spectrometry. These advanced tests generally provide more detailed and sensitive information, but confirmatory enzyme and molecular testing may still be required.

Normal Reporting Time

The report for the Mucopolysaccharides (MPS) Screen Qualitative - Urine test is generally available within 3 to 5 working days. Turnaround time may vary according to sample transport, laboratory workload, batch schedules, repeat testing and whether the specimen is referred to a specialised metabolic laboratory.

Who Should Consider This Test?

• Infants or children with unexplained developmental delay or loss of acquired skills.
• Patients with short stature, abnormal bone development or progressive joint stiffness.
• Children with recurrent hernias, frequent respiratory infections or enlarged liver and spleen.
• Patients with coarse facial features, corneal clouding, hearing loss or heart-valve abnormalities.
• Individuals with a family history of mucopolysaccharidosis or another lysosomal storage disorder.
• Patients with an abnormal newborn screen requiring further metabolic evaluation.
• Anyone advised to undergo testing by a paediatrician, neurologist, geneticist or metabolic specialist.

Understanding the Test Results

Negative or Normal Screen: A negative result means that the qualitative method did not identify a clearly abnormal mucopolysaccharide finding in the submitted specimen. This reduces the likelihood of some MPS disorders but does not exclude them completely. Mild disease, certain MPS subtypes, older patient age, diluted urine or limitations of the screening method can produce false-negative results.

Positive or Abnormal Screen: A positive result indicates increased urinary mucopolysaccharides or an abnormal pattern requiring further assessment. It does not specify the exact MPS type and is not sufficient for a final diagnosis. Other clinical or analytical factors can sometimes produce non-specific abnormalities.

After an abnormal screen, the doctor may request quantitative urine GAG measurement and fractionation to determine which glycosaminoglycans are increased. Specific lysosomal enzyme assays in leukocytes, plasma, cultured fibroblasts or dried blood spots may then identify the deficient enzyme. Molecular genetic testing can confirm the causal gene variants and support family counselling.

If the screen is negative but clinical suspicion remains strong, further testing should not be abandoned. Modern quantitative GAG assays, targeted enzyme studies or genetic panels may be appropriate because qualitative urine screening has limited sensitivity for certain disease types and attenuated presentations.

Clinical Limitations

A qualitative MPS urine screen is a preliminary test rather than a definitive diagnostic investigation. It may not identify every mucopolysaccharidosis. False-negative results can occur in mild disease, attenuated phenotypes, older patients, dilute urine samples and disorders that produce relatively small or method-specific changes in urinary GAGs.

False-positive or non-specific results can occur because urinary GAG excretion is influenced by age, illness, urine concentration and analytical technique. Young children naturally have higher GAG excretion than adults. The result must therefore be evaluated using age-appropriate criteria.

The screening test cannot reliably identify carrier status, predict disease severity or determine inheritance. It also cannot distinguish all MPS subtypes. A confirmed diagnosis generally requires demonstration of deficient enzyme activity and identification of disease-causing genetic variants.

Normal urine screening does not override a strong clinical pattern. The referring physician should discuss persistent suspicion with a biochemical genetics or metabolic specialist. Early specialist involvement can help ensure that the correct GAG, enzyme and molecular investigations are selected.

Important Safety Information

This test is intended to support evaluation by qualified healthcare professionals and should not be used for self-diagnosis. Parents should not assume that a positive screen confirms a serious inherited disorder or that a negative screen excludes one. Every result should be discussed with the referring paediatrician or metabolic specialist.

Seek urgent medical care if a child develops breathing difficulty, severe sleep-related breathing problems, seizures, loss of consciousness, sudden weakness, persistent vomiting, dehydration or rapid clinical deterioration. Patients with suspected cervical spine instability should follow specialist precautions before anaesthesia, surgery or activities involving forceful neck movement.